An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Exclusion Criteria

• •Prior Treatment: Previous treatment with Ivosidenib.
• •Cancer Type: Ampulla of Vater cancer.
• •Pregnancy： Pregnant or breastfeeding women.
• •Allergy: Known hypersensitivity to any component of the study drugs.
• •Recent Therapy: Local anti-tumor therapy or major surgery within 4 weeks prior to initiation.
• •Medical Conditions:
• •Uncontrolled hypertension.
• •Significant cardiovascular disease.
• •Active or untreated CNS metastases.
• •Active autoimmune disease.
• •Uncontrolled active infection (e.g., HBV, HCV, HIV).
• •Significant bleeding tendency or history.
• •Severe non-healing wounds.
• •History of organ transplantation.
• •Concurrent Participation: Participation in another interventional clinical trial.